Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Lefkowitz

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Clinical Genitourinary Cancer|May 26, 2022
MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After ProstatectomyAndreas G Wibmer, Robert A Lefkowitz, Yulia Lakhman, et al.
Academic Radiology|March 20, 2003
Routine editing of trainee-generated radiology reports: effect on style qualityFergus V Coakley, Stefan B Heinze, Clair L Shadbolt, et al.
Cancer Chemotherapy and Pharmacology|October 19, 2010
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridolMark A Dickson, Manish A Shah, Dana Rathkopf, et al.
The Journal of Urology|November 18, 2020
Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging FindingsAndreas G Wibmer, Joshua Chaim, Yulia Lakhman, et al.
The Oncologist|August 24, 2023
Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced CancersNaryan Rustgi, Ann Maria, Nicolas Toumbacaris, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
Sarcoma|June 16, 2015
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue SarcomaMark A Dickson, David R D'Adamo, Mary L Keohan, et al.
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Cancer Discovery|June 23, 2019
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon CancerYijun Gao, Ann Maria, Na Na, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Clinical Genitourinary Cancer|May 26, 2022
MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After ProstatectomyAndreas G Wibmer, Robert A Lefkowitz, Yulia Lakhman, et al.
Academic Radiology|March 20, 2003
Routine editing of trainee-generated radiology reports: effect on style qualityFergus V Coakley, Stefan B Heinze, Clair L Shadbolt, et al.
Cancer Chemotherapy and Pharmacology|October 19, 2010
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridolMark A Dickson, Manish A Shah, Dana Rathkopf, et al.
The Journal of Urology|November 18, 2020
Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging FindingsAndreas G Wibmer, Joshua Chaim, Yulia Lakhman, et al.
The Oncologist|August 24, 2023
Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced CancersNaryan Rustgi, Ann Maria, Nicolas Toumbacaris, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
Sarcoma|June 16, 2015
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue SarcomaMark A Dickson, David R D'Adamo, Mary L Keohan, et al.
The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.
Cancer Discovery|June 23, 2019
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon CancerYijun Gao, Ann Maria, Na Na, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Pageof 6